Logan Coy Related postsAn Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR MutationsSeptember 11, 2026A Phase 2, Randomized, Open-label Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic SyndromeSeptember 11, 2026A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Low-Dose Lenalidomide (STAR-LLD) for the Treatment of Multiple MyelomaSeptember 11, 2026 Previous postA Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Mature B-Cell MalignanciesNext postA Phase 1 Study of IM-1021 in Participants with Advanced Malignancies